AmerisourceBergen Corporation

Nestled in Riverside, RI, Cardinal Health stands as a beacon of health and wellness for the community. This pharmacy exudes a sense of reliability and expertise, catering to the diverse needs of its customers. From prescription medications to over-the-counter remedies, this establishment offers a wide array of pharmaceutical solutions to promote well-being. With a prime location in Riverside, RI, Cardinal Health serves as a vital resource for those seeking professional pharmacy services. The knowledgeable staff members are dedicated to providing top-notch care and guidance, ensuring that every visitor receives personalized attention. Whether you're in need of medication counseling or simply looking to refill a prescription, this pharmacy is a trusted destination for all your health-related needs. Generated using this place's available information

Akcea Therapeutics, Inc., based in Boston, MA, is a pioneering biopharmaceutical company dedicated to designing and developing highly selective small molecule medicines aimed at improving patient outcomes in oncology, immunology, and metabolic disorders. With a track record of success, the company applies leading-edge technologies and rigorous methodologies to enhance target selection and drug discovery processes. The organization's commitment to excellence is reflected in its expert leadership and collaborative culture, fostering a unique environment where talent is valued. Through meticulous attention to selectivity—whether in people, targets, or potential drug molecules—Akcea Therapeutics continues to push the boundaries of medical innovation. Generated from the website

Alexion Pharmaceuticals is engaged in the discovery and development of therapeutic products aimed at treating patients with an array of diseases, including hematologic and cardiovascular disorders, autoimmune diseases and cancer. Alexion's two primary product candidates, pexelizumab and eculizumab, are currently undergoing evaluation in several clinical development programs with the Federal Drug Administration. Alexion is engaged in discovering and developing a pipeline of additional antibody therapeutics targeting severe unmet medical needs, through its wholly owned subsidiary, Alexion Antibody Technologies. During the fiscal year ended July 31, 2005, eculizumab was in Phase III clinical development for treatment of paroxysmal nocturnal hemoglobinuria , a chronic hematologic disease, and pexelizumab was in clinical development for two acute cardiac indications. Alexion is also pursuing additional potential indications for eculizumab and has other product candidates in earlier stages of development. Alexion Pharmaceuticals is based in Cheshire, Conn.